MEDP Medpace Holdings, Inc.
Legal ·
Defendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped.
We have not published a story on Medpace Holdings yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.53 billion | $2.11 billion |
| Net income (loss) | $451.1 million | $404.4 million |
| Cash from operations | $713.2 million | $608.8 million |
| Cash and equivalents | $497.0 million | $669.4 million |
Our latest story on this, dated Oct 22, 2026: "Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio". The story links the filing or release it is based on. Read the story.
Medpace Holdings, Inc. trades under the ticker MEDP on NASDAQ.
Medpace Holdings, Inc. is listed on NASDAQ.
Our directory records Medpace Holdings, Inc. under United States.
aibio.space lists Medpace Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$2.53 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Medpace Holdings, Inc. reported net income of $451.1 million for the fiscal year ended Dec 31, 2025, and generated $713.2 million of cash from operations, per its annual report to the SEC.
$705.3 million in cash at Sep 30, 2026, per its 10-Q.
Our latest story on Medpace Holdings, dated Oct 22, 2026: "Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio". Defendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped. Source.
Press Follow on this page to add Medpace Holdings to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Medpace Holdings so far, in Legal.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio